News

Technology News

BioDelivery Sciences Announces FDA Approval Of ONSOLIS

Friday, July 17, 2009 5:17:00 AM PDT | VentureDeal Staff
Raleigh, North Carolina  --  Biotechnology firm BioDelivery Sciences International (NASDAQ: BDSI) has announced the approval from the FDA to market a new pain drug.

Called ONSOLIS and designed for a thin film applications to the inner lining of the cheek for cancer patients 18 years of age or older, the drug is an alternative to opioid therapy for persistent cancer pain.

“The approval of ONSOLIS is a landmark and transformational event for BDSI and represents the culmination of an extraordinary and focused effort by a determined group of BDSI and Meda employees,” said Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences. “All of us at BDSI, along with our partner Meda, are very pleased to provide healthcare practitioners and their patients suffering from breakthrough cancer pain with a new treatment option for this serious and debilitating condition.”

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1